This question evaluates hepatic dose adjustment for lorazepam in a patient with severe liver disease. The key patient-specific factor is Child-Pugh class C cirrhosis with laboratory evidence of severe hepatic dysfunction, including elevated bilirubin and low albumin. The correct answer is 1.5 mg/day, calculated by taking the usual total daily dose of 3 mg/day (1 mg every 8 hours = 3 mg/day) and reducing it by 50% as specified (3 mg × 0.5 = 1.5 mg/day). Option A (0.5 mg/day) incorrectly reduces the dose by approximately 83%, which is excessive. Option C (3 mg/day) fails to implement any dose reduction despite severe hepatic impairment. Option D (4.5 mg/day) incorrectly increases the dose by 50% rather than reducing it. For benzodiazepines in hepatic impairment, dose reductions of 50% or more are often necessary due to decreased metabolism and increased sensitivity, with lorazepam being preferred over other benzodiazepines due to its simpler metabolic pathway.

This question evaluates opioid conversion from oral morphine to transdermal fentanyl using established conversion ratios. The key factor is calculating the total daily morphine dose and applying the appropriate conversion to fentanyl. The correct answer is fentanyl patch 50 mcg/hour because the patient takes 30 mg every 6 hours = 120 mg/day of oral morphine, and using the conversion that 25 mcg/hour fentanyl ≈ 60 mg/day oral morphine, the equivalent is 120 mg ÷ 60 mg × 25 mcg/hour = 50 mcg/hour. Option A (25 mcg/hour) would only replace 60 mg/day of morphine, providing half the needed analgesia. Option C (75 mcg/hour) would be equivalent to 180 mg/day morphine, a 50% increase. Option D (100 mcg/hour) would double the opioid exposure to 240 mg morphine equivalents daily. When converting to fentanyl patches, calculate the total daily morphine dose first, then use conservative conversion ratios and monitor closely, as individual variation in fentanyl absorption and metabolism can be significant.

This question tests weight-based dose calculation with a maximum cap for pediatric antiparasitic therapy. The key patient-specific factor is the child's weight of 25 kg, which determines the dose up to the 1 g maximum. The correct dose is 275 mg once because 11 mg/kg × 25 kg = 275 mg, below the max. Choice A is incorrect as it miscalculates to about 4.4 mg/kg. Choices C and D are wrong; C doubles it, and D exceeds unnecessarily. Multiply mg/kg by weight and apply caps to avoid overdose. Educate on single-dose administration and hygiene to prevent reinfection in pinworm treatment.

This question tests renal dose adjustment for analgesic therapy. The key patient-specific factor is the creatinine clearance of approximately 22 mL/min, calculated via Cockcroft-Gault using age, weight, and SCr. Adjusting to 75 mg twice daily is accurate as it reduces the daily dose to 150 mg, aligning with maximum recommendations for CrCl 15-30 mL/min to avoid sedation. Choice B is incorrect as continuing 150 mg twice daily (300 mg/day) exceeds the max for low CrCl. Choices C and D are wrong; C increases frequency, and D reduces excessively to once daily. Use the female multiplier (0.85) in Cockcroft-Gault for accurate CrCl in women. Titrate pregabalin slowly in elderly with renal issues, monitoring for CNS side effects.

This question tests dose conversion from oral to intravenous formulation for antibiotic therapy. The key patient-specific factor is intubation preventing oral intake, necessitating IV administration. The equivalent IV dose is 600 mg every 12 hours because linezolid has 100% bioavailability, allowing 1:1 conversion. Choice A is incorrect as it halves the dose, risking treatment failure. Choices C and D are wrong; C doubles it, and D reduces frequency. For bioequivalent formulations, maintain dose and frequency in conversions. Monitor platelets weekly during linezolid therapy due to myelosuppression risk.

This question tests dose conversion from oral to intravenous formulation for antiemetic therapy. The key patient-specific factor is the NPO status with severe nausea, necessitating IV administration. The equivalent IV dose is 10 mg four times daily because metoclopramide has high bioavailability, allowing 1:1 conversion. Choice A is incorrect as it halves the dose, reducing prokinetic effect. Choices C and D are wrong; C doubles it, and D halves frequency. Use direct equivalence for drugs with similar IV and PO pharmacokinetics. Monitor for extrapyramidal symptoms, especially in females and prolonged use.

This question tests dose conversion from oral to intravenous formulation for antibiotic therapy. The key patient-specific factor is the NPO status for a procedure, necessitating IV administration. The equivalent IV dose is 100 mg every 12 hours because doxycycline has high bioavailability, allowing 1:1 conversion. Choice A is incorrect as it halves the dose, potentially reducing efficacy against MRSA. Choices C and D are wrong; C doubles it, and D reduces frequency. Maintain dose and interval for bioequivalent conversions. No renal adjustment needed for doxycycline, unlike some antibiotics.

This question tests renal dose adjustment for antidiabetic therapy. The key patient-specific factor is the creatinine clearance of approximately 28 mL/min, calculated via Cockcroft-Gault using age, weight, and SCr. Discontinuing metformin is accurate as it is contraindicated for CrCl <30 mL/min due to lactic acidosis risk. Choice A is incorrect as continuing risks toxicity in AKI. Choices B and C are wrong; they reduce but do not eliminate use in contraindicated clearance. Use actual body weight in calculations unless adjusted for obesity. Assess for alternative therapies like insulin in renal impairment and diabetes.

This question tests dose conversion from oral to intravenous corticosteroid using potency equivalence. The key patient-specific factor is the inability to take oral meds due to BiPAP, necessitating IV administration. The equivalent IV dose is 32 mg daily because prednisone 5 mg = methylprednisolone 4 mg, so 40 mg prednisone = 32 mg methylprednisolone. Choice C is incorrect as it ignores the 5:4 ratio, using 1:1. Choices A and D are wrong; A halves incorrectly, and D uses a 4:5 ratio reversal. Apply standard glucocorticoid equivalence ratios for accurate conversions. Monitor glucose levels during corticosteroid therapy, especially in COPD exacerbations.

This question tests renal dose adjustment for gout prophylaxis. The key patient-specific factor is the creatinine clearance of approximately 28 mL/min, calculated via Cockcroft-Gault using age, weight, and SCr. Adjusting to 0.3 mg once daily is accurate as it matches recommendations for CrCl <30 mL/min to prevent toxicity. Choice A is incorrect as continuing twice daily risks accumulation. Choices B and D are wrong; B halves incorrectly, and D doubles the daily amount. Calculate CrCl precisely in elderly males without the female multiplier. Use lowest effective doses of colchicine in renal impairment to minimize gastrointestinal side effects.